Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
100 μg | 約5 days | ¥ 187,000 |
500 μg | 約5 days | ¥ 746,000 |
1 mg | 約5 days | ¥ 1,248,500 |
説明 | Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4. |
Species | Cynomolgus |
Expression Host | HEK293 Cells |
Tag | C-His |
Accession Number | A0A2K5UDJ4 |
別名 | Igifbp, Interleukin-18-binding protein, IL-18BP |
Construction | Thr28-Pro207 |
Protein Purity | > 95% as determined by Tris-Bis PAGE; > 90% as determined by HPLC |
分子量 | 21.14 kDa (predicted). Due to glycosylation, the protein migrates to 50-65 kDa based on Tris-Bis PAGE result. |
Endotoxin | < 1 EU/μg by the LAL method. |
Formulation | Supplied as 0.22 μm filtered solution in PBS (pH 7.4). |
Stability & Storage |
It is recommended to store the product under sterile conditions at -70℃ or lower. Samples are stable for up to 12 months at -80℃. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping |
In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
Research Background | Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated Igifbp Interleukin-18-binding protein IL-18BP recombinant recombinant-proteins proteins protein